Fortifying p53 - beyond Mdm2 inhibitors.
Institute of Molecular Oncology, Göttingen Center of Molecular Biosciences (GZMB), University Medical Center Göttingen, D-37077 Göttingen, Germany.
Anusha
A
Sriraman
Institute of Molecular Oncology, Göttingen Center of Molecular Biosciences (GZMB), University Medical Center Göttingen, D-37077 Göttingen, Germany.
Yizhu
Y
Li
Institute of Molecular Oncology, Göttingen Center of Molecular Biosciences (GZMB), University Medical Center Göttingen, D-37077 Göttingen, Germany.
Matthias
M
Dobbelstein
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D000071636:Protein Phosphatase 2C / Q000235:genetics / Q000378:metabolism; D051736:Proto-Oncogene Proteins c-mdm2 / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism*
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2; C000607458:PPM1D protein, human; D000071636:Protein Phosphatase 2C
Mdm2; PPM1D; Wip1; cancer treatment; p53
Nat Chem Biol. 2014 Mar;10 (3):181-7
24390428
Oncotarget. 2016 Mar 22;7(12):14458-75
26883108
Mol Cancer Ther. 2016 Mar;15(3):379-91
26832796
Science. 2004 Feb 6;303(5659):844-8
14704432
Cancer Cell. 2007 Oct;12 (4):342-54
17936559
Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1888-93
16443686
Oncotarget. 2016 May 31;7(22):31623-38
27183917